LncRNA PTS-1 Protects Against Osteoarthritis Through the miR-8085/E2F2 Axis.

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Osteoarthritis (OA) is a debilitating condition characterized by metabolic imbalances in chondrocytes, extracellular matrix (ECM), and subchondral bone.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their significant role in the pathogenesis of OA.

Purpose of the Study:

• To investigate the function and regulatory mechanisms of the novel long non-coding RNA, lnc-PTS-1, in the progression of osteoarthritis.
• To elucidate the molecular interactions involving lnc-PTS-1 in the context of OA.

Main Methods:

• RNA sequencing and qRT-PCR were used to assess lncRNA expression profiles.
• Cellular assays (viability, proliferation, apoptosis) and molecular analyses (mRNA/protein levels of ECM, apoptosis, and inflammation markers) were performed.
• Dual luciferase reporter assays and RNA immunoprecipitation (RIP) were employed to investigate molecular interactions.

Main Results:

• Lnc-PTS-1 expression was significantly downregulated in OA cartilage and chondrocytes.
• Lnc-PTS-1 knockdown exacerbated OA hallmarks, while its overexpression conferred protection.
• Lnc-PTS-1 functions as a competing endogenous RNA (ceRNA) by sponging miR-8085, thereby upregulating E2F2.

Conclusions:

• The lnc-PTS-1/miR-8085/E2F2 axis represents a novel regulatory mechanism in osteoarthritis pathogenesis.
• These findings provide a theoretical basis and experimental evidence for the potential clinical application of lncRNAs in OA treatment.